A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats

Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes

(2015) B. Bode et al.   DIABETES OBESITY & METABOLISM

Long-Term Reduction of High Blood Pressure by Angiotensin II DNA Vaccine in Spontaneously Hypertensive RatsNovelty and Significance

(2015) Hiroshi Koriyama et al.   HYPERTENSION

Effect of dipeptidyl peptidase-4 inhibition on circadian blood pressure during the development of salt-dependent hypertension in rats

(2015) Abu Sufiun et al.   HYPERTENSION RESEARCH

SGLT2 inhibitors: their potential reduction in blood pressure

(2015) George Maliha et al.   Journal of the American Society of Hypertension

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice

(2014) Bowen Lin et al.   Cardiovascular Diabetology

Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis

(2014) A. Liakos et al.   DIABETES OBESITY & METABOLISM

Blood pressure effects of sodium–glucose co-transport 2 (SGLT2) inhibitors

(2014) Raymond V. Oliva et al.   Journal of the American Society of Hypertension

Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes

(2014) David Z.I. Cherney et al.   KIDNEY INTERNATIONAL

Regression of Glomerular and Tubulointerstitial Injuries by Dietary Salt Reduction with Combination Therapy of Angiotensin II Receptor Blocker and Calcium Channel Blocker in Dahl Salt-Sensitive Rats

(2014) Kazi Rafiq et al.   PLoS One

The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity

(2014) Matthias Oelze et al.   PLoS One

Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models

(2014) M Suzuki et al.   Nutrition & Diabetes

Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes

(2013) Despoina Vasilakou et al.   ANNALS OF INTERNAL MEDICINE

Novel Metabolic Drugs and Blood Pressure: Implications for the Treatment of Obese Hypertensive Patients?

(2013) Stefan Engeli et al.   CURRENT HYPERTENSION REPORTS

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

(2013) H. J. Lambers Heerspink et al.   DIABETES OBESITY & METABOLISM

Proposal of a new strategy for ambulatory blood pressure profile-based management of resistant hypertension in the era of renal denervation

(2013) Kazuomi Kario   HYPERTENSION RESEARCH

Long‐Term Renal Denervation Normalizes Disrupted Blood Pressure Circadian Rhythm and Ameliorates Cardiovascular Injury in a Rat Model of Metabolic Syndrome

(2013) Tetsuji Katayama et al.   Journal of the American Heart Association

Novel Mechanism for Disrupted Circadian Blood Pressure Rhythm in a Rat Model of Metabolic Syndrome—The Critical Role of Angiotensin II

(2013) Daisuke Sueta et al.   Journal of the American Heart Association

Angiotensin Receptor Blockade Increases Pancreatic Insulin Secretion and Decreases Glucose Intolerance during Glucose Supplementation in a Model of Metabolic Syndrome

(2012) Ruben Rodriguez et al.   ENDOCRINOLOGY

Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin

(2012) Jan Bolinder et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Weight Loss Induced by Chronic Dapagliflozin Treatment Is Attenuated by Compensatory Hyperphagia in Diet-Induced Obese (DIO) Rats

(2012) James J. Devenny et al.   Obesity

Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat

(2011) Scott C. Thomson et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

(2011) R. Grempler et al.   DIABETES OBESITY & METABOLISM

SGLT2 Mediates Glucose Reabsorption in the Early Proximal Tubule

(2010) V. Vallon et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Effects of Dietary Sodium Reduction on Blood Pressure in Subjects With Resistant Hypertension

(2009) Eduardo Pimenta et al.   HYPERTENSION

Metabolic syndrome and salt sensitivity of blood pressure in non-diabetic people in China: a dietary intervention study

(2009) Jing Chen et al.   LANCET